Naari Pharma acquires ten ANDAs from Intas Pharmaceuticals


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ naari-pharma-acquires-intas-pharmaceuticals-andas-aiming-us-market
The portfolio acquired from INTAS comprises eight US FDA approved ANDAs and two products pending approval

Naari Pharma has entered into a definitive asset purchase agreement to acquire 10 Abbreviated New Drug Applications (ANDAs) for the US market from Intas Pharmaceuticals.

The portfolio acquired comprises eight US FDA approved ANDAs and two products pending approval. It includes generic products in female hormones which will be manufactured at Naari’s dedicated female hormone facility in India and commercialized over the next 24 months.

Naari is a vertically integrated global women’s health pharmaceutical business focused on hormones and has development and manufacturing capabilities across intermediates, active pharmaceutical ingredients, and finished dosage forms (FDFs).

Prithi S Kochhar, Co-Founder and CEO, Naari, said, “This is great news for us and another milestone in our journey towards becoming a leading global player in the field of women’s health. This is an important step towards developing our US portfolio.“With these newly acquired ANDAs, we now have market access of $ 900 million as per IQVIA data.”

The acquisition follows a planned period of significant growth and investment for Naari. In October 2019 Naari acquired three ANDAs from OC Pharm in the US and in February 2020 the company announced that it had received an equity investment of $ 17.5 million from Ascent Capital, a leading India-focussed growth capital provider.

Kochhar continued, “Our journey into the US market is well charted and we expect sales and a positive growth trajectory beginning in the next 12 months.

“We now have all the key enablers in place towards achieving our revenue target of $ 100 million in the next four to five years, which should make us one of the top women’s health companies in the world and enable us to continue providing vital products to support women’s health across the globe.”

With a presence in more than 50 countries and over 30 hormonal generics currently available or under development, Naari has one of the most comprehensive hormonal portfolios in the world.

Tags : #IntasPharmaceuticals #NaariPharma #WomenHealth #USFDA #Anda

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026